PALO ALTO, Calif., Oct. 11, 2013 /PRNewswire/ --CardioDx, Inc. announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed initial public offering of its common stock. All of the shares to be sold in the proposed offering will be offered by CardioDx. The number of shares to be offered and the price range for the offering have not yet been determined. CardioDx has applied for a listing of its common stock on The NASDAQ Stock Market under the symbol "CDX".
(Logo: http://photos.prnewswire.com/prnh/20130219/MM60898 )
BofA Merrill Lynch and Jefferies LLC will act as joint book-running managers for the offering. Piper Jaffray & Co. and William Blair & Company, L.L.C. will act as co-managers for the offering.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy these securities be accepted prior to the time the registration statement becomes effective. The offering will be made only by means of a prospectus. A copy of the preliminary prospectus relating to the offering, when available, may be obtained from either: BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, or by email at dg.prospectus_requests@baml.com; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Ave, 12th Floor, New York, NY 10022, telephone: 877-547-6340, or by email at Prospectus_Department@Jefferies.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About CardioDx
CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, is committed to developing clinically validated tests that empower clinicians to improve treatment decisions. Strategically focused initially on diagnostics for coronary artery disease (CAD), cardiac arrhythmia and heart failure, CardioDx is committed to providing healthcare professionals with critical, actionable information to improve patient care and management through the commercialization of genomic technologies. CardioDx's Corus® CAD test is the first and only commercially available blood-based gene expression test that provides a current-state assessment for non-diabetic patients with symptoms that are suggestive of obstructive CAD. Corus CAD helps clinicians rule out obstructive CAD as the cause of these symptoms.
SOURCE CardioDx, Inc.
